U.S. court affirms Sanofi's Eloxatin patent until 2012

Sanofi's ($SNY) Eloxatin is safe from generic competition in the U.S. until August 2012. A federal court denied Sun Pharmaceuticals' appeal in a patent dispute over the colon cancer drug, which brought in $349 million in the the second quarter, Reuters said. Report

Suggested Articles

Johnson & Johnson and Bayer’s Xarelto is working to reverse a sales slide, and a new indication could help.

AZ's FluMist will be dramatically limited in the U.S. this flu season because of production problems, a spokeswoman said.

To get its $12 billion opioid deal off the ground, Purdue Pharma pushed for a stay on thousands of lawsuits against it. Last week, a judge signed off.